Intellia Therapeutics (NTLA) Other Accumulated Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Other Accumulated Expenses data on file, last reported at $8.1 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $8.1 million, up 167.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (up 167.72% YoY), and the FY2025 annual result was $17.4 million, up 737.72% from the prior year.
• Other Accumulated Expenses fell to $8.1 million in Q1 2026 per NTLA's latest filing, from $17.4 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $30.3 million in Q3 2022 and troughed at $2.1 million in Q4 2024.
• A 5-year average of $12.3 million and a median of $8.1 million in 2026 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses surged 1179.88% in 2022, then plunged 92.44% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $5.0 million in 2022, then surged by 452.98% to $27.4 million in 2023, then sank by 92.44% to $2.1 million in 2024, then soared by 737.72% to $17.4 million in 2025, then sank by 53.33% to $8.1 million in 2026.
• Business Quant data shows NTLA's Other Accumulated Expenses at $8.1 million in Q1 2026, $17.4 million in Q4 2025, and $15.7 million in Q3 2025.